Ofer Agid

Summary

Affiliation: Centre for Addiction and Mental Health
Country: Canada

Publications

  1. ncbi Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
  2. ncbi Emerging drugs for schizophrenia
    Ofer Agid
    Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Expert Opin Emerg Drugs 13:479-95. 2008
  3. ncbi An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, M5T 1R8, Canada
    J Clin Psychiatry 72:1439-44. 2011
  4. ncbi Where to position clozapine: re-examining the evidence
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 55:677-84. 2010
  5. ncbi Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Expert Opin Pharmacother 11:2301-17. 2010
  6. ncbi Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    Ofer Agid
    Center for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 102:241-8. 2008
  7. ncbi Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
  8. ncbi Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011
  9. ncbi Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia
    Romina Mizrahi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5S 2S1
    Am J Psychiatry 164:630-7. 2007
  10. ncbi The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study
    Ariel Graff-Guerrero
    PET Centre, Centre for Addiction and Mental Health, Toronto, Canada
    Neuropsychopharmacology 34:1078-86. 2009

Detail Information

Publications23

  1. ncbi Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
    ....
  2. ncbi Emerging drugs for schizophrenia
    Ofer Agid
    Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Expert Opin Emerg Drugs 13:479-95. 2008
    ..As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned...
  3. ncbi An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, M5T 1R8, Canada
    J Clin Psychiatry 72:1439-44. 2011
    ..Employing a naturalistic design, we examined response rates over 3 circumscribed antipsychotic trials...
  4. ncbi Where to position clozapine: re-examining the evidence
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 55:677-84. 2010
    ..To review clozapine's position in treatment algorithms for schizophrenia...
  5. ncbi Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Expert Opin Pharmacother 11:2301-17. 2010
    ..However, nonadherence with antipsychotic treatment is a significant issue, with estimates as high as 90%...
  6. ncbi Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    Ofer Agid
    Center for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 102:241-8. 2008
    ..The objective of this study was to evaluate the early response (within the first 24 h) in psychosis with ziprasidone IM treatment, and to determine whether this early effect is distinct from a reduction in agitation symptoms...
  7. ncbi Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
    ....
  8. ncbi Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011
    ..Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia...
  9. ncbi Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia
    Romina Mizrahi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5S 2S1
    Am J Psychiatry 164:630-7. 2007
    ..The authors present the first double-blind controlled study to examine the relationship between striatal and extrastriatal dopamine D(2) receptor binding potential and occupancy values and adverse subjective experience...
  10. ncbi The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study
    Ariel Graff-Guerrero
    PET Centre, Centre for Addiction and Mental Health, Toronto, Canada
    Neuropsychopharmacology 34:1078-86. 2009
    ..It is possible that receptors with high affinity are not accessible by [(11)C]-(+)-PHNO because they are occupied by endogenous dopamine, a possibility that can be ruled out in future experiments...
  11. ncbi Clozapine's role in the treatment of first-episode schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 170:146-51. 2013
    ....
  12. ncbi Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Neuropsychopharmacology 32:1209-15. 2007
    ....
  13. ncbi Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO
    Romina Mizrahi
    PET Centre, Centre for Addiction and Mental Health, Toronto, Canada
    Schizophr Res 131:63-8. 2011
    ..11)C]-(+)-PHNO offer new opportunities for exploring the potential therapeutic significance of the D(3) receptor in schizophrenia and the action of antipsychotics...
  14. ncbi Happiness in first-episode schizophrenia
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    Schizophr Res 141:98-103. 2012
    ..The present study set out to specifically assess happiness in schizophrenia in relation to both clinical and functional measures of outcome...
  15. ncbi Evidence for onset of antipsychotic effects within the first 24 hours of treatment
    Shitij Kapur
    Centre for Addiction and Mental Health, 250 College St, Toronto, Ont, Canada M5R 1T8
    Am J Psychiatry 162:939-46. 2005
    ..Recent research has shown that antipsychotic action begins within the first week. The authors tested the hypothesis that psychosis improves within the first 24 hours of antipsychotic treatment...
  16. ncbi Progress in defining optimal treatment outcome in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:9-20. 2010
    ..To this end, the field has now embraced a recovery model that is seen as a process, multidimensional and individualized, rather than dichotomous and symptom driven...
  17. ncbi Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected
    Ofer Agid
    Schizophrenia Program and the PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Gen Psychiatry 60:1228-35. 2003
    ..Furthermore, greater improvement occurs in the first 2 treatment weeks than in the subsequent 2 treatment weeks. Proposed mechanisms of action of antipsychotic drugs need to account for this early-onset antipsychotic effect...
  18. ncbi Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment
    Gary Remington
    University of Toronto, Toronto, Ontario, Canada
    Expert Rev Neurother 11:589-607. 2011
    ..This shift in thinking has important theoretical implications from the standpoint of etiology and pathophysiology, but also clinically in terms of treatment and drug development...
  19. ncbi How antipsychotics work-from receptors to reality
    Shitij Kapur
    Centre for Addiction and Mental Health, Toronto, Canada M5S 1A1 University of Toronto, Toronto, Canada
    NeuroRx 3:10-21. 2006
    ..The implications of these findings for clinical care, animal models, future target discovery and drug development are discussed...
  20. ncbi Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 225:505-18. 2013
    ..A safety-related threshold has also been proposed, as well as therapeutic lower and upper thresholds. While there has been reasonable consensus regarding a lower therapeutic threshold, this is not the case for the upper thresholds...
  21. ncbi Specialized home treatment versus hospital-based outpatient treatment for first-episode psychosis: a randomized clinical trial
    Carolyn S Dewa
    Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
    Early Interv Psychiatry 3:304-11. 2009
    ..This pilot study compared the effectiveness of specialized care that was home based versus hospital based for individuals experiencing their first psychotic episode...
  22. ncbi The "delayed onset" of antipsychotic action--an idea whose time has come and gone
    Ofer Agid
    Centre for Addiction and Mental Health, Toronto, Ont
    J Psychiatry Neurosci 31:93-100. 2006
    ..The implications of this finding for clinical decision-making, mechanisms of antipsychotic action and drug discovery are discussed...
  23. ncbi Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics
    Johannes Tauscher
    University of Toronto Department of Psychiatry, Schizophrenia Program
    Am J Psychiatry 161:1620-5. 2004
    ....